Sugi Predict

Sugi Predict / Compounds / 2-Phthalimidoglutaramic Acid

2-Phthalimidoglutaramic Acid

2-Phthalimidoglutaramic Acid

SCHEMBL442029

NC(=O)CC[C@@H](C(=O)O)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.77
▸ POLB P06746 4/20 0.77
▸ KDM4E B2RXH2 1/20 0.77
▸ TP53 P04637 1/20 0.77
▸ GLA P06280 1/20 0.77
▸ CYP3A4 P08684 1/20 0.77
▸ CYP2D6 P10635 1/20 0.77
▸ HPGD P15428 1/20 0.77
▸ ALOX12 P18054 1/20 0.77
▸ NFKB1 P19838 1/20 0.77
▸ APEX1 P27695 1/20 0.77
▸ MAPK1 P28482 1/20 0.77
▸ HSD17B10 Q99714 1/20 0.77
▸ KMT2A Q03164 3/20 0.74
▸ MEN1 O00255 1/20 0.74
▸ GAA P10253 2/20 0.60
▸ L3MBTL1 Q9Y468 2/20 0.57
▸ HIF1A Q16665 1/20 0.50
▸ DNMT1 P26358 4/20 0.48
▸ CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Phthalimidoglutaramic Acid SCHEMBL411177 1.00 ALDH1A1 (0.77) ALDH1A1POLBKDM4ETP53GLA
2-Phthalimidoglutaramic Acid SCHEMBL14855879 1.00 ALDH1A1 (0.77) ALDH1A1POLBKDM4ETP53GLA
2-Phthalimidoglutaramic Acid SCHEMBL410627 1.00 ALDH1A1 (0.77) ALDH1A1POLBKDM4ETP53GLA
2-Phthalimidoglutaramic Acid SCHEMBL410167 1.00 ALDH1A1 (0.77) ALDH1A1POLBKDM4ETP53GLA
SCHEMBL30978209 0.89 ALDH1A1 (0.63) ALDH1A1POLBKDM4ETP53GLA
SCHEMBL441970 0.87 ALDH1A1 (1.00) ALDH1A1POLBKDM4ETP53GLA
SCHEMBL411110 0.87 ALDH1A1 (1.00) ALDH1A1POLBKDM4ETP53GLA
SCHEMBL14991107 0.87 ALDH1A1 (1.00) ALDH1A1POLBKDM4ETP53GLA
SCHEMBL29763164 0.87 ALDH1A1 (1.00) ALDH1A1POLBKDM4ETP53GLA
SCHEMBL411173 0.87 ALDH1A1 (1.00) ALDH1A1POLBKDM4ETP53GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3067411-A1 METHOD FOR ADAPTING A HYDROLYTIC ENZYME TO A COMPONENT STABILISING THE HYDROLYTIC ENZYME Henkel AG & Co. KGaA (DE) 2016-09-14 — — EP claimed
US-20150218126-A1 CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION GENERICS [UK] LIMITED (GB) 2015-08-06 — — US claimed
EP-2756064-A2 METHOD FOR ADAPTING A HYDROLYTIC ENZYME TO A COMPONENT THAT STABILIZES THE HYDROLYTIC ENZYME Henkel AG & Co. KGaA (DE) 2014-07-23 — — EP claimed
US-20130143923-A1 CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION GENERICS [UK] LIMITED (GB) 2013-06-06 — — US claimed
EP-2598623-A2 STABILIZED LIQUID TENSIDE PREPARATION COMPRISING ENZYMES Henkel AG & Co. KGaA (DE) 2013-06-05 — — EP claimed
CN-103068812-A Crystalline forms of thalidomide and processes for their preparation GENERICS UK LTD 2013-04-24 — — CN claimed
EP-2580205-A1 CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION Generics [UK] Limited (GB) 2013-04-17 — — EP claimed
WO-2013037609-A2 METHOD FOR ADAPTING A HYDROLYTIC ENZYME TO A COMPONENT THAT STABILIZES THE HYDROLYTIC ENZYME HENKEL AG & CO. KGAA (DE) 2013-03-21 — — WO claimed
WO-2012019847-A2 STABILIZED LIQUID TENSIDE PREPARATION COMPRISING ENZYMES HENKEL AG & CO. KGAA (DE) 2012-02-16 — — WO claimed
WO-2011154739-A1 CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION GENERICS [UK] LIMITED (GB) 2011-12-15 — — WO claimed
CN-1298737-C Synthesis method of dipeptide containing L-glutamine NANJING UNIVERSITY OF TECHNOLOGY (CN) 2007-02-07 — — CN claimed
CN-1264810-C Process for synthesis of L-glutamine NANJING UNIVERSITY OF TECHNOLOGY (CN) 2006-07-19 — — CN claimed
CN-1651456-A Synthesis method of dipeptide containing L-glutamine NANJING UNIVERSITY OF TECHNOLOGY (CN) 2005-08-10 — — CN claimed
CN-1569820-A Process for synthesis of L-glutamine NANJING UNIVERSITY OF TECHNOLOGY (CN) 2005-01-26 — — CN claimed
EP-1477486-A2 Imides as inhibitors of TNF alpha CELGENE CORPORATION (US) 2004-11-17 — — EP claimed
EP-1004581-B1 Process for the preparation of thalidomide CELGENE CORP (US) 2004-09-22 — — EP claimed
EP-1004581-A2 Process for the preparation of thalidomide CELGENE CORPORATION (US) 2000-05-31 — — EP claimed
EP-0706521-A1 NOVEL IMIDES CELGENE CORPORATION (US) 1996-04-17 — — EP claimed
US-5463063-A Preparation of thalidomide; inhibitor of tumor necrosis factor CELGENE CORPORATION (US) 1995-10-31 — — US claimed
WO-1995001348-A2 IMIDES AS INHIBITORS OF TNP ALPHA CELGENE CORPORATION (US) 1995-01-12 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143923-A1 CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION TNF, UACA, VEGFA ALDH1A1 2821/4885POLB 2597/4885KDM4E 2791/4885
US-20150218126-A1 CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION TNF, UACA, VEGFA ALDH1A1 2821/4885POLB 2597/4885KDM4E 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.